In an adult with type 2 diabetes and chronic kidney disease (eGFR ≥ 30 mL/min/1.73 m²), how does dapagliflozin (Farxiga) compare to finerenone (Kerendia) regarding efficacy, safety, and optimal sequencing or combination use?

Farxiga (Dapagliflozin) is Superior to Kerendia (Finerenone) for Type 2 Diabetes with CKD

For adults with type 2 diabetes and chronic kidney disease (eGFR ≥30 mL/min/1.73 m²), dapagliflozin (Farxiga) should be the first-line cardiorenal protective agent, with finerenone (Kerendia) reserved as add-on therapy only after SGLT2 inhibitor initiation. This recommendation is based on the 2025 BMJ living guideline which provides a strong recommendation for SGLT2 inhibitors in high-risk patients and explicitly recommends against finerenone monotherapy in moderate-risk CKD patients 1.

Evidence Hierarchy and Strength

The most recent 2025 BMJ guideline 1 analyzed 110 trials with 86,803 participants for SGLT2 inhibitors versus only 2 trials with 13,026 participants for finerenone. This guideline makes clear distinctions:

• SGLT2 inhibitors receive a strong recommendation for high-risk patients with established CVD or CKD, based on high-certainty evidence of mortality benefit and moderate-to-high certainty evidence for cardiovascular and kidney outcomes 1

• Finerenone receives a weak recommendation against use in moderate-risk CKD patients, citing "little or no benefit" (moderate-to-high certainty), risk of severe hyperkalemia, and limited clinical experience 1

Mortality and Morbidity Outcomes

Dapagliflozin (Farxiga)

The DAPA-CKD trial 2 demonstrated that dapagliflozin in 4,304 CKD patients (with or without diabetes) achieved:

• 39% reduction in composite kidney outcomes (HR 0.61,95% CI 0.51-0.72, P<0.001)
• 31% reduction in all-cause mortality (HR 0.69,95% CI 0.53-0.88, P=0.004)
• 29% reduction in cardiovascular death or heart failure hospitalization (HR 0.71,95% CI 0.55-0.92, P=0.009)
• Number needed to treat: 19 patients to prevent one primary outcome event

Finerenone (Kerendia)

The FIDELIO-DKD trial 3 in 5,734 patients showed:

• 18% reduction in kidney outcomes (HR 0.82,95% CI 0.73-0.93, P=0.001)
• 14% reduction in cardiovascular outcomes (HR 0.86,95% CI 0.75-0.99, P=0.03)
• No mortality benefit demonstrated
• 2.3% discontinuation rate due to hyperkalemia versus 0.9% with placebo

The magnitude of benefit is clearly greater with dapagliflozin, particularly for mortality—the most important patient-centered outcome.

Sequencing Algorithm

Step 1: Initiate dapagliflozin 10 mg daily as first-line cardiorenal protection in all patients with T2D and CKD (eGFR ≥25 mL/min/1.73 m²) 4

Step 2: Ensure maximally tolerated RAS inhibitor (ACE-I or ARB) is already on board

Step 3: Consider adding finerenone only if:

• Patient remains on dapagliflozin for ≥3-6 months
• Albuminuria persists (UACR >300 mg/g or nephrotic-range proteinuria)
• Serum potassium consistently <4.5 mmol/L
• eGFR decline continues despite SGLT2 inhibitor therapy

Combination Therapy Evidence

Recent real-world data suggests potential synergy when combining both agents, but this is secondary to SGLT2 inhibitor initiation:

• Triple therapy (RAS inhibitor + dapagliflozin + finerenone) in DKD patients with nephrotic-range proteinuria showed 55-60% reduction in proteinuria at 12 months without serious hyperkalemia 5

• Finerenone added to SGLT2 inhibitors demonstrated 84.9% of patients achieving ≥50% UACR reduction versus 45.5% with SGLT2 inhibitor alone 6

• However, patients with rapid pre-treatment eGFR decline experienced accelerated deterioration when finerenone was added (mean difference -6.28 mL/min/1.73 m²/year) 7

Critical Safety Considerations

Dapagliflozin

• Genital mycotic infections (2-10%, dose-dependent) 8
• Euglycemic DKA (rare but serious—avoid in insulin-deficient states, prolonged fasting, surgery) 8
• Volume depletion risk in elderly or those with eGFR 30-60 4
• Initial eGFR dip of ~5 mL/min (returns to baseline, then slower decline) 8

Finerenone

• Hyperkalemia is the primary concern: 2.3% discontinuation rate 3
• Requires potassium monitoring: baseline, at 1 month, then every 3-4 months
• Contraindicated if baseline K+ >5.0 mmol/L
• Use extreme caution with other potassium-sparing agents

Common Pitfalls to Avoid

1. Do not start finerenone before SGLT2 inhibitor unless SGLT2 inhibitor is contraindicated (extremely rare in this population)

2. Do not withhold dapagliflozin due to initial eGFR dip—this is expected hemodynamic effect and predicts long-term kidney protection 8

3. Do not add finerenone in patients with rapid eGFR decline (>5 mL/min/1.73 m²/year) without careful monitoring, as this may accelerate deterioration 7

4. Do not use finerenone monotherapy in moderate-risk CKD—the guideline explicitly recommends against this 1

5. Monitor potassium aggressively when combining therapies—check at baseline, 1 month, then quarterly

Quality of Life Considerations

Dapagliflozin offers additional benefits beyond cardiorenal protection:

• Modest weight loss (glucose excretion of 60-100 g/day) 8
• Reduced heart failure symptoms and hospitalizations
• Once-daily oral dosing with minimal monitoring requirements

Finerenone requires more intensive monitoring (potassium checks) and has no weight or glycemic benefits, making it less favorable from a treatment burden perspective.

The evidence unequivocally supports dapagliflozin as first-line therapy, with finerenone reserved as adjunctive therapy in select patients with persistent albuminuria despite optimal SGLT2 inhibitor and RAS blockade.